Symbolbild · KI-generiert
Organogenesis Holdings Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Organogenesis is a US medical technology company specialising in regenerative medicine, manufacturing products for wound care and tissue repair. Its products include bioactive wound dressings and tissue replacement materials, used primarily in the treatment of chronic and acute wounds.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Organogenesis Holdings Inc. | ORGO | NASDAQ | 305 Mio. USD |
| Cipher Pharmaceuticals Inc. | CPH | TSX | 305 Mio. USD |
| Opus Genetics, Inc. | IRD | NASDAQ | 306 Mio. USD |
| Vanda Pharmaceuticals Inc. | VNDA | NASDAQ | 307 Mio. USD |
| Vitalhub Corp. | VHI | TSX | 309 Mio. USD |
| Sanara MedTech Inc. | SMTI | NASDAQ | 310 Mio. USD |
| Neumora Therapeutics, Inc. | NMRA | NASDAQ | 298 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.